Imagine trying to prove that sharing your secret recipes helps the whole neighborhood eat better, not just your competitors. This work creates a guidebook and a set of tools to track exactly how making research public leads to real-world money and social gains. It's like a GPS for seeing how a free piece of data turns into a new product or a better law.
Companies and funders struggle to prove the actual financial value of sharing data and research. Without a way to measure the causal link between 'openness' and 'profit/impact', many stick to closed, slower systems.
An OS Impact Indicator Handbook and a cost-benefit analysis (CBA) tool for measuring the economic and social returns of open research.
If you are a biotech firm dealing with high costs of data discovery — this project developed an indicator handbook that identifies how open bioinformatics data, like ELIXIR, creates economic benefits. This helps you quantify the value of using public data versus paying for private sets.
If you are an AI developer dealing with the need for high-quality training sets — this project developed a way to track the impact of open climate-AI research. You can use these methods to see how open datasets accelerate your product development cycle.
If you are an agency dealing with justifying research budgets — this project developed a cost-benefit analysis (CBA) methodology. This allows you to prove the economic return of funding open research infrastructures to taxpayers.
Based on available project data, no specific commercial pricing is mentioned as the project focused on developing methodologies and a public resource hub.
The project tested its methods through 6 case studies across different domains, including industry visibility for RCAAP infrastructure, suggesting the methods are designed for broad application.
Based on available project data, the project promotes Open Science and provides a resource hub, implying a focus on open access rather than restrictive licensing.
It provides policy recommendations and evidence-based indicators to help EU policy makers prioritize Open Science adoption.
The project operated over a period from 2022-09-01 to 2025-08-31 to validate these pathways, indicating that impact measurement is a multi-year process.
The consortium is research-heavy with 5 research organizations and 2 universities, but maintains a 20% industry ratio with 2 industrial partners and 4 SMEs. This balance suggests the tools were developed with academic rigor but validated against actual business needs across 8 European countries.
Contact ATHINA-EREVNITIKO KENTRO KAINOTOMIAS for the OS Impact Indicator Handbook
Contact us to get the CBA methodology for your R&I portfolio.
